01—Abstract
Summary
Summary of the 8-K filed April 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Amgen reported first quarter 2026 results that beat the prior-year period on the bottom line, with total revenues up 6% to $8.6 billiona, GAAP EPS up 4% to $3.34, and non-GAAP EPS up 5% to $5.15.
Product sales grew 4% to $8.2 billionb, driven by 9% volume growth partially offset by 2% lower net selling price and 2% lower inventory. Sixteen products grew at least double digits, led by volume gains in Repatha, Uplizna, Imdelltra, Tepezza, and Tezspire. Profitability was strong: GAAP operating margin rose 17.4 points to 32.4%, largely because of lower acquisition-related amortization and a prior-year $800 million Otezla impairment, while non-GAAP operating margin edged down 0.4 points to 45.3%.
Free cash flow rose to $1.5 billionc from $1.0 billion, and debt climbed to $57.3 billion as cash reached $12.0 billion. The main risks are concentrated in legacy franchises and one regulatory matter. Prolia (down 34%), XGEVA (down 27%), and Enbrel (down 37%) face accelerating erosion from biosimilar competition and Medicare Part D price setting under the Inflation Reduction Act.
The FDA has proposed withdrawing approval of TAVNEOS, citing questions about the evidence of effectiveness and the accuracy of ChemoCentryx's original application, and it also issued a Drug Safety Communication on fatal liver injury cases. Amgen says TAVNEOS will remain on the market during the review and that it intends to contest the proposal. Full-year 2026 guidance was reiterated with non-GAAP EPS of $21.70 to $23.10d and revenue of $37.1 billion to $38.5 billion, and the company is advancing a late-stage pipeline including MariTide Phase 3 obesity studies.
For investors, the quarter shows underlying volume momentum in newer launches offsetting pricing and biosimilar pressure on the legacy base. The TAVNEOS regulatory process is the key near-term event to monitor, along with the pace of erosion in Prolia and XGEVA and execution on the MariTide program. No share repurchases were made in the quarter, and the dividend rose 6% to $2.52 per share.
02—Key points
Key Highlights
- Total revenues rose 6% to $8.6 billion; product sales grew 4% to $8.2 billion, with 9% volume growth offset by 2% lower net selling price.
- GAAP EPS increased 4% to $3.34 and non-GAAP EPS increased 5% to $5.15, with non-GAAP operating margin of 45.3% (down 0.4 points).
- GAAP operating income more than doubled to $2.7 billion (margin 32.4%), helped by lower acquisition amortization and the absence of a prior-year $800 million Otezla impairment.
- Free cash flow was $1.5 billion versus $1.0 billion a year earlier; cash rose to $12.0 billion while debt increased to $57.3 billion.
- Legacy franchises are eroding: Prolia down 34%, XGEVA down 27%, and Enbrel down 37%, with management expecting accelerated Prolia and XGEVA erosion in 2026 from biosimilar competition.
- FDA proposed withdrawing approval of TAVNEOS (April 27 proposal, Federal Register notice April 30); Amgen intends to contest, and the drug remains on the market during the process.
- 2026 guidance reiterated: non-GAAP EPS of $21.70 to $23.10, total revenues of $37.1 billion to $38.5 billion, and share repurchases of up to $3.0 billion; no buybacks were made in Q1.
03—Questions
Frequently Asked Questions
Why did GAAP operating margin jump so much year over year?
The prior-year quarter included an $800 million impairment of Otezla intangible assets and heavier acquisition-related amortization. Lower amortization and the absence of that impairment drove GAAP operating margin up 17.4 points to 32.4%. On a non-GAAP basis, which excludes these items, margin was roughly flat at 45.3%.
What is the risk from the FDA proposal to withdraw TAVNEOS?
TAVNEOS generated $119 million in Q1 2026 sales (up 32%). The FDA has proposed withdrawal, citing lack of substantial evidence of effectiveness and alleged untrue statements in the original application, and the process includes a possible hearing request. Amgen says the drug stays on the market during the review. Separately, the FDA has flagged fatal liver injury cases, and Amgen filed a label update (CBE-30) on April 29. The financial impact depends on the outcome of the hearing and any label changes.
Is Amgen on track for its 2026 guidance?
The company reiterated full-year guidance, but the release does not state whether it was raised or lowered. Q1 non-GAAP EPS of $5.15 is a small part of the $21.70 to $23.10 range, and the quarter's strong volume growth in newer products supports the outlook. However, Prolia, XGEVA, and Enbrel erosion and pricing pressure are headwinds that could affect the back half of the year.
Why did free cash flow improve, and what about debt?
Free cash flow rose to $1.5 billion from $1.0 billion, driven by business performance and working capital timing, partly offset by higher capital expenditures of $712 million. Debt rose to $57.3 billion from $54.6 billion at year-end 2025, and the company made no share repurchases during the quarter. Investors should watch whether the working capital benefit reverses later in the year.
What drives the outlook for the MariTide obesity program?
MariTide is in multiple Phase 3 studies (MARITIME-1, -2, -CV, -HF, -OSA-1 and -2, plus switch and extension studies), with three more Phase 3 T2D studies planned for 2026. R&D expense rose 16% in Q1, mainly due to spending on later-stage programs including MariTide. Results from these trials will be a key driver of long-term growth, but they are not expected in this quarter.
04—Continue